Decitabine: a promising epi-immunotherapeutic agent in solid tumors. (March 2015)

• Record Type: Journal Article
• Authors: Li, Xiang; Mei, Qian; Nie, Jing; Fu, Xiaobing; Han, Weidong
• Is Part Of: Expert review of clinical immunology. Volume 11:Number 3(2015)
• Page Start: 363
• Page End: 375
• Publication Date: 2015-03
• Subjects: Clinical immunology -- Periodicals; 616.079
• DOI: 10.1586/1744666X.2015.1002397
• Languages: English
• ISSNs: 1744-666X

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>The incidence of malignancies is increasing worldwide. Despite early detection, surgical resection, chemotherapy and radiotherapy, numerous patients continue to die from metastasis or recurrence. The immune system has the capacity to eradicate cancer cells; however, many tumors, especially solid tumors, present considerable challenges that render immune cells ineffectual, making cancer cells almost 'invisible' to the immune system. Compelling evidence has demonstrated that DNA methylation is involved in tumor development and progression, leading to the impaired immunogenicity and immune recognition of cancer cells. The hypomethylating agent decitabine has been shown to have therapeutic effects in malignancies and exhibits an effective immune efficacy in eliminating cancer cells. Based on the hypomethylating and immune remodeling effects of decitabine, we propose in this review that decitabine can be considered an epi-immunotherapeutic agent. We summarize the results of recent preclinical studies and clinical trials for decitabine and discuss the connections among its hypomethylating effect, immune-activated mechanisms and clinical activity in solid tumors, keeping in mind the goal of optimizing dosing schedules.</p> </abstract>